SEOM clinical guidelines for the treatment of thyroid cancer

Clinical and Translational Oncology

Volumn 13, Issue 8, 2011, Pages 574-579

  Trufero, Javier Martínez ^a   Capdevilla, Jaume ^a,b   Cruz, Juan Jesús ^c   Isla, Dolores ^d  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Diagnosis; Staging; Thyroid cancer; Treatment

Indexed keywords

AXITINIB; CABOZANTINIB; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; IODINE 131; LENALIDOMIDE; MOTESANIB; PAZOPANIB; PLACEBO; SORAFENIB; STREPTOZOCIN; SUNITINIB; VANDETANIB;

ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; DIFFERENTIATED THYROID CANCER; DIFFERENTIATED THYROID FOLICULAR CANCER; DIFFERENTIATED THYROID HURTHLE CANCER; DIFFERENTIATED THYROID PAPILLARY CANCER; FOLLOW UP; HUMAN; ISTHMUSECTOMY; LOBECTOMY; LYMPHADENECTOMY; PRACTICE GUIDELINE; SUBTOTAL THYROIDECTOMY; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROID SURGERY; THYROIDECTOMY; TUMOR BIOPSY; ADULT; MEDICAL SOCIETY; MEDULLARY CARCINOMA; METHODOLOGY; MIDDLE AGED; ONCOLOGY; THYROID TUMOR; TREATMENT OUTCOME;

ADULT; CARCINOMA, MEDULLARY; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; SOCIETIES, MEDICAL; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84855404529     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0700-3     Document Type: Article

References (34)

1. Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167
2. National Cancer Institute Web site. Thyroid Cancer. http://seer.cancer. gov/statfacts/html/thyro.html. Accessed 06/04/08
3. Davidson BJ, Burman KD (2003) Cancer of thyroid and parathyroid. In: Harrison LB, Sessions RB, Hong WK et al (eds) Head and neck cancer: a multidisciplinary approach. Wolters Kluwer/Lippincott, Philadelphia, PA
4. Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York, p 87-96
5. Robbins RJ. Wan Q, Grewal RK et al (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucosepositron emission tomography scanning. J Clin Endocrinol Metab 91:498-505 (Pubitemid 43236915)
6. National Comprehensive Cancer Network (2007) Clinical practice guidelines in oncology. Thyroid carcinoma, V.2.2007. AJCC 6th edn. www.nccn.org/ professionals/physician-gls/PDF/thyroid.pdf
7. Carling T, Udelsman R (2005) Thyroid tumors. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Williams and Wilkins, Philadelphia, p 1502-1520
8. Sherman SI, Tutle RM, Ball DW et al (2008) NCCN practice guidelines for thyroid carcinoma. NCCN, www.nccn.org
9. Staunton MD (1994) Thyroid cancer: a multivariate analysis on influence of treatment on longterm survival. Eur J Surg Oncol 20:613-621
10. Jonklaas J, Sarlis NJ, Litofsky D et al (2006) Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229-1242 (Pubitemid 46080167)
11. McGriff NJ, Csako G, Gourgiotis L et al (2002) Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34:554-564 (Pubitemid 36113813)
12. Shimaoka K, Schoenfeld D, DeWys WD et al (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160 (Pubitemid 16236586)
13. Cohen EW, Rosen LS, Vokes EE (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
14. Gupta-Abramson V, Troxel AB, Nellore A (2008) Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
15. Kloos RT, Ringel MD, Knopp MV et al (2009) Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
16. Sherman SI, Wirth LJ, Droz JP et al (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Eng J Med 359:31-42 (Pubitemid 351931094)
17. Cohen EE, Needles B, Cullen K et al (2008) Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 26:abstr 6025
18. Ravaud A, de la Fouchardiere C, Courbon F et al (2008) Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol 26:abstr 6058
19. Ain KB, Lee C, Williams KD (2007) Phase II trial of thalidomide for therapy of radioiodineunresponsive and rapidly progressive thyroid carcinomas. Thyroid 17:663-670 (Pubitemid 47311556)
20. Orlandi F, Caraci P, Berruti A et al (1994) Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 5:763-765 (Pubitemid 24302696)
21. Wu LT, Averbuch SD, Ball DW et al (1994) Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73:432-436 (Pubitemid 24030625)
22. Cohen EW, Rosen LS, Vokes EE (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
23. Cohen EE, Needles B, Cullen K et al (2008) Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 26:abstr 6025
24. Hadadd R, Krebs A, Vasselli J et al (2008) A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 26:abstr 6024
25. Wells SA, Gosnell JE, Gagel RF et al (2007) Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 25:303s
26. Schlumberger MJ, Elisei R, Bastholt L et al (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801
27. Lam ET, Ringel MD, Kloos RT et al (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330
28. Wells SA Jr, Robinson BG, Gosnell et al (2010) Vandetanib in locally advanced or metastasic medullary thyroid cancer: a randomized double blind Phase III trial (ZETA). J Clin Oncol 28:15s
29. Lang BH, Lo CY (2007) Surgical options in undifferentiated thyroid carcinoma. World J Surg 31:969-977 (Pubitemid 46716788)
30. Lim S, Lee NY, Fury MG et al (2007) Doxorubicin and concurrent radiotherapy for anaplastic thyroid cancer: we need to do better. J Clin Oncol 25:669s
31. Tennvall J, Lyndell G, Wahlberg P et al (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86:1848-1853
32. Cooney M, Savvides P, Agarwala S et al (2006) Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol 24:abstr 5580
33. Tuttle RM, Ball DW, Byrd D et al (2010) National Comprehensive Cancer Network. Thyroid carcinoma. J Natl Compr Canc Netw 8:1228-1274
34. Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612. Review. Erratum 19:1295